I assumed (maybe incorrectly) that the question was aked with regard to fatloss rather than mass gain. In either case womens hormones, just like mens, are subject to pretty sensitive feedback machanisms to ensure that hormonal balance is maintained. Many obese women have high circulating estrogen levels due to aromitization of test and androstendione. They often also have higher test levels. This is undeniable. However high levels of peripherally produced estrogen merely act to supress ovarian production so that overall estrogen balance is more or less maintained. This is one of the reason that obesity causes infertility in women. Giving a drug like Arimidex will reduce peripheral aromitization but lead to increased ovarian estrogen production to maintain balance. Increases in test levels will be transient as most of this test is produced by the ovaries and is also subject to feedback inhibition, especially when ovarian estrogen levels return to normal. If you really, really want to kill estrogen production in an otherwise healthy adult female you will need to give her a luteinising hormone-releasing hormone (LH-RH) analogue such as Triptorelin. But before you consider any of these drugs you should read some of the literature (and I don't mean the stuff you find in BB chat rooms) and decide for yourself if it even makes sense at any level to inhibit peripheral aromatase activity in a female:
Obes Res 2002 Feb;10(2):115-21
The lean woman.
OBJECTIVE: In the current obesity epidemic, the ability to remain lean is beginning to be uncommon. Therefore, it was considered of interest to characterize such subjects.
RESEARCH METHODS AND PROCEDURES: From a population of premenopausal women (n = 270), all 40 years of age, those with a similar body mass index (BMI) as women at the age of 21 years, born the same year were selected among nonsmokers and compared with the remaining (non-lean) nonsmoking women.
RESULTS: Lean women showed, as expected, low waist-to-hip circumference ratio and abdominal sagittal diameter as well as absence of other disease risk factors. COMPARED WITH THE REMAINING (NON-LEAN) WOMEN, 17 BETA-ESTRADIOL WAS HIGH AND ANDROGENS WERE LOW, whereas insulin-like growth factor I and thyroid hormones showed no differences. Dihydroepiandrosterone sulfate was lower, whereas cortisol, measured in saliva repeatedly over a day, and adrenocorticotropin hormone were not different. Results from questionnaires indicated higher education and socioeconomic status, frequent sports activities, and better psychosocial adaptation and psychological health. A tetranucleotide repeat polymorphism in the fourth [corrected] intron of the aromatase P450 gene was longer among the lean (187 base pairs) than the rest of the women. Women with opposite phylogenetic characteristic have a short microsatellite (168 base pairs) in this gene locus.
DISCUSSION: Lean, nonsmoking women enjoy an excellent health in not only anthropometric and metabolic factors, but also in neuroendocrine, endocrine, and psychological variables. THE ENDOCRINE MEASUREMENTS (OF LEAN WOMEN) SUGGEST A WELL-FUNCTIONING AROMATASE ENZYME, which in turn might have a genetic background, contributing to health. THE AROMATASE GENE MIGHT BE IMPORTANT FOR REGULATION OF A LEAN PHENOTYPE.
Ann N Y Acad Sci 2001 Dec;949:58-67
Tissue-specific estrogen biosynthesis and metabolism.
While the OVARIES ARE THE PRINCIPAL SOURCE OF SYSTEMIC ESTROGEN in the premenopausal nonpregnant woman, other sites of estrogen biosynthesis are present throughout the body and these become the major sources of estrogen beyond menopause. These EXTRAGONADAL SOURCES OF ESTROGEN ARE SMALL, but may play an important, though hitherto largely unrecognized, physiological and pathophysiological role.in POSTmenopausal women Aromatase activity in extragonadal sites contributes to this source of estrogen and may contribute to tumor development and/or growth………... …………………..
Please Scroll Down to See Forums Below 
.. am still reviewing the materials.. only so much time in a day
